{
    "clinical_study": {
        "@rank": "132802", 
        "arm_group": {
            "arm_group_label": "MLN8237", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is an open-label, multicenter, phase 1 study with the primary objective of evaluating\n      the effect of food on the single-dose PK properties of alisertib administered as the ECT\n      formulation. The secondary objective is to further evaluate the safety and tolerability of\n      alisertib."
        }, 
        "brief_title": "Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Advanced Solid Tumors", 
            "Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 years or older\n\n          -  Histologically or cytologically confirmed advanced tumors or lymphomas for which\n             standard curative or life-prolonging treatment does not exist, or is no longer\n             effective or tolerable\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n\n          -  Patient must meet protocol-specified laboratory values\n\n          -  Female patients who are postmenopausal for at least 1 year OR are surgically sterile\n             OR if of childbearing potential, agree to practice 2 effective methods of\n             contraception at the same time or agree to practice true abstinence\n\n          -  Male patients who agree to practice effective barrier contraception during the entire\n             study and through 4 months after the last dose of study drug OR agree to practice\n             true abstinence\n\n        Exclusion Criteria:\n\n          -  Prior or current investigational therapies within 4 weeks before the first dose of\n             alisertib\n\n          -  Female patients who are lactating or pregnant\n\n          -  Patient requiring treatment with clinically significant enzyme inducers, such as the\n             enzyme-inducing antiepileptic drugs phenytoin, carbamazepine, or phenobarbital, or\n             rifampin, rifabutin, rifapentine, or St. John's wort within 14 days before the first\n             dose of alisertib and during the study\n\n          -  Medical conditions requiring daily, chronic, or regular use of proton pump\n             inhibitors(PPIs) within 7 days preceding the first dose of alisertib, or H2-receptor\n             antagonists\n\n          -  Patient requiring systemic anticoagulation\n\n          -  Ongoing nausea or vomiting that is Grade 2 or worse in intensity\n\n          -  Known GI disease or GI procedures that could interfere with the oral absorption,\n             excretion, or tolerance of alisertib\n\n          -  History of uncontrolled sleep apnea syndrome and other conditions that could result\n             in excessive daytime sleepiness such as severe chronic obstructive pulmonary disease\n\n          -  Known or suspected human immunodeficiency virus (HIV) positive or hepatitis B surface\n             antigen-positive status, or known or suspected active hepatitis C infection\n\n          -  Patients who are lactose-intolerant or are unwilling/unable to consume the protocol\n             specified standardized high-fat breakfast\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01898078", 
            "org_study_id": "C14017"
        }, 
        "intervention": {
            "arm_group_label": "MLN8237", 
            "description": "Patients will be randomly assigned in a crossover fashion to receive a single 50-mg dose of alisertib (administered as 5 x 10 mg enteric-coated tablets) with or without a standard high-fat breakfast on Day 1 of Cycle 1, with the respective alternate food intake condition (fasted to fed, or fed to fasted; n = approximately 9 per sequence) on Day 1 in Cycle 2.", 
            "intervention_name": "MLN8237", 
            "intervention_type": "Drug", 
            "other_name": "alisertib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "MLN8237", 
            "alisertib", 
            "food effects"
        ], 
        "lastchanged_date": "February 11, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Sanjay Goel"
                }, 
                "facility": {
                    "address": {
                        "city": "Lake Success", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11041"
                    }, 
                    "name": "Montefiore Medical Center PRIME"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Todd Bauer"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "John Sarantopoulos"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229-3271"
                    }, 
                    "name": "Institute for Drug Devt Cancer Therapy & Research Ctr"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label, Phase 1, Two-Way, Cross-Over Study of the Effect of the Food on the Pharmacokinetics of MLN8237 (Alisertib) in Patients With Advanced Solid Tumors or Lymphomas", 
        "overall_contact": {
            "email": "medical@mlnm.com", 
            "last_name": "For an updated listing of recruitment sites contact: Millennium  Medical and Drug Information Center", 
            "phone": "1-877-674-3784"
        }, 
        "overall_official": {
            "affiliation": "Millennium Pharmaceuticals, Inc.", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Ratio of geometric mean maximum plasma concentration (Cmax) of alisertib with food versus without food and associated 90% confidence intervals (CI)", 
                "safety_issue": "No", 
                "time_frame": "Days 1 through 4 of Cycles 1 & 2"
            }, 
            {
                "measure": "Ratio of geometric mean area under the plasma concentration versus time curve zero to the time of the last measurement (AUC0-last) of alisertib with food versus without food and associated 90% CI", 
                "safety_issue": "No", 
                "time_frame": "Days 1 through 4 of Cycles 1 & 2"
            }, 
            {
                "measure": "Ratio of geometric mean area under the plasma concentration versus time curve zero to infinity (AUC0-inf) of alisertib with food versus without food and associated 90% CI", 
                "safety_issue": "No", 
                "time_frame": "Days 1 through 4 of Cycles 1 & 2"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01898078"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Evaluation of safety and tolerability of alisertib following single and multiple doses. Safety and tolerability as assessed by evaluation of adverse events (AEs), changes in laboratory values, and vital signs.", 
            "safety_issue": "Yes", 
            "time_frame": "Recorded from first dose of study drug through 30 days after the last dose of study drug"
        }, 
        "source": "Millennium Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Millennium Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}